MCID: HPT021
MIFTS: 69

Hepatitis malady

Categories: Gastrointestinal diseases, Liver diseases, Genetic diseases, Rare diseases, Immune diseases, Skin diseases, Infectious diseases

Aliases & Classifications for Hepatitis

Aliases & Descriptions for Hepatitis:

Name: Hepatitis 38 12 29 52 41 14 69
Chronic Persistent Hepatitis 12 52 69
Acute Hepatitis 12 29 69
Hepatitis, Chronic 42 69
Chronic Hepatitis 12 14
Acute and Subacute Liver Necrosis 12
Acute/subac. Necrosis of Liver 12
Hepatitis Chronic 52
Hepatitis, Animal 69
Animal Hepatitis 12
Hepatitis a 69

Classifications:



Summaries for Hepatitis

MedlinePlus : 41 your liver is the largest organ inside your body. it helps your body digest food, store energy, and remove poisons. hepatitis is an inflammation of the liver. viruses cause most cases of hepatitis. the type of hepatitis is named for the virus that causes it; for example, hepatitis a, hepatitis b or hepatitis c. drug or alcohol use can also cause hepatitis. in other cases, your body mistakenly attacks healthy cells in the liver. some people who have hepatitis have no symptoms. others may have loss of appetite nausea and vomiting diarrhea dark-colored urine and pale bowel movements stomach pain jaundice, yellowing of skin and eyes some forms of hepatitis are mild, and others can be serious. some can lead to scarring, called cirrhosis, or to liver cancer. sometimes hepatitis goes away by itself. if it does not, it can be treated with drugs. sometimes hepatitis lasts a lifetime. vaccines can help prevent some viral forms.

MalaCards based summary : Hepatitis, also known as chronic persistent hepatitis, is related to b-cell lymphomas and malignant glioma, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Hepatitis is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are NF-kappaB Signaling and Hepatitis C. The drugs Aluminum hydroxide and Cyclosporine have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and kidney.

Wikipedia : 71 Hepatitis is inflammation of the liver tissue. Some people have no symptoms whereas others develop... more...

Related Diseases for Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1536)
id Related Disease Score Top Affiliating Genes
1 b-cell lymphomas 30.2 F2 GPT SEPSECS
2 malignant glioma 29.1 IFNA1 IFNA2
3 acute monocytic leukemia 29.1 F2 GPT SLC17A5
4 exophthalmos 29.0 CD81 GPT IFNA1 IFNA2 TNF
5 hemolytic-uremic syndrome 28.9 AFP F2 GPT HAVCR1 HAVCR2 IFNA2
6 hereditary hemorrhagic telangiectasia 28.7 AFP CCDC85B CD81 CLDN1 F2 GPT
7 hepatitis c 12.3
8 hepatitis b 12.3
9 autoimmune hepatitis 12.3
10 viral hepatitis 12.3
11 hepatitis a 12.3
12 hepatitis d 12.3
13 alcoholic hepatitis 12.2
14 hepatic encephalopathy 12.2
15 hepatic lipase deficiency 12.2
16 hepatitis c virus 12.2
17 hepatic veno-occlusive disease 12.2
18 hepatic venoocclusive disease with immunodeficiency 12.1
19 hepatitis e 12.1
20 congenital hepatic fibrosis 12.1
21 renal-hepatic-pancreatic dysplasia 12.1
22 non-a-e hepatitis 12.1
23 polycystic kidney and hepatic disease 12.0
24 epstein-barr virus hepatitis 12.0
25 hepatic adenoma, somatic 11.9
26 granulomatous hepatitis 11.9
27 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovasuclar malformations 11.9
28 hepatic coma 11.9
29 renal-hepatic-pancreatic dysplasia 2 11.9
30 porphyria, acute hepatic 11.9
31 drug-induced hepatitis 11.9
32 hepatic flexure cancer 11.9
33 renal-hepatic-pancreatic dysplasia 1 11.9
34 cpt deficiency, hepatic, type ii 11.9
35 hepatic tuberculosis 11.9
36 fulminant viral hepatitis 11.8
37 liver disease 11.8
38 hepatic infarction 11.8
39 hepatic angiomyolipoma 11.8
40 cpt deficiency, hepatic, type ia 11.8
41 sclerosing hepatic carcinoma 11.7
42 hepatic vascular disease 11.7
43 hepatocellular carcinoma 11.7
44 primary hepatic neuroendocrine carcinoma 11.7
45 coach syndrome 11.7
46 acute liver failure 11.7
47 glycogen storage disease iv 11.7
48 hepatic cystic hamartoma 11.6
49 hepatic failure, early-onset, and neurologic disorder due to cytochrome c oxidase deficiency 11.6
50 chronic end-stage hepatitis c 11.6

Comorbidity relations with Hepatitis via Phenotypic Disease Network (PDN): (show all 16)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Cholangitis Chronic Myocardial Ischemia
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Hypothyroidism
Ischemic Heart Disease Mitral Valve Disease
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatitis:



Diseases related to Hepatitis

Symptoms & Phenotypes for Hepatitis

UMLS symptoms related to Hepatitis:


abdominal pain, constipation, diarrhea, dyspepsia, fever, heartburn, hepatosplenomegaly, icterus, nausea and vomiting, pruritus, gastrointestinal gas, hepatocellular jaundice, lameness, animal

Drugs & Therapeutics for Hepatitis

Drugs for Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 775)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved Phase 4,Phase 3,Phase 2,Phase 1 21645-51-2
2
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
5
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1 99210-65-8, 215647-85-1
6
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
7
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142340-99-6 60871
8
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
9
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147127-20-6 464205
10
Isoniazid Approved Phase 4,Phase 3,Phase 2 54-85-3 3767
11
Pyrazinamide Approved Phase 4 98-96-4 1046
12
Rifampin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5458213 5381226
13
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
14
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198153-51-4 5360545
15
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
16
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
17
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3424-98-4 159269
18
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
19
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
20
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
21
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
22
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
23
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
24
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
25
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
26
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
27
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 83-43-2 6741
28
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-24-8 5755
29
Ethiodized oil Approved Phase 4,Phase 3,Phase 2 8008-53-5
30
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
31
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
32
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
33
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
34
Pentoxifylline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 6493-05-6 4740
35
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
36
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
37
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128-13-2 31401
38
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
39
Simvastatin Approved Phase 4,Phase 3,Phase 1 79902-63-9 54454
40
Insulin Glargine Approved Phase 4 160337-95-1
41
Insulin-glulisine Approved Phase 4 207748-29-6
42
Zinc Approved Phase 4,Phase 2,Phase 3 7440-66-6 32051 23994
43
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
44
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
45
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1 923604-59-5 66576988
46
Sofosbuvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1190307-88-0 45375808
47
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1 1256388-51-8 67505836
48
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
49
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
50
Thymalfasin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 62304-98-7

Interventional clinical trials:

(show top 50) (show all 3935)
id Name Status NCT ID Phase
1 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
2 PCV13 + Hepatitis A Vaccine for Adults Unknown status NCT01926860 Phase 4
3 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
4 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
5 Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine(Hecolin®) Unknown status NCT02189603 Phase 4
6 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4
7 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4
8 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4
9 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
10 Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus Unknown status NCT01488526 Phase 4
11 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4
12 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
13 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4
14 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4
15 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4
16 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4
17 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4
18 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4
19 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4
20 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4
21 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4
22 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4
23 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4
24 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4
25 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4
26 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4
27 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
28 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4
29 Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B Unknown status NCT01926288 Phase 4
30 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4
31 A Two-year Study of Telbivudine in HBeAg Negative Hepatitis Unknown status NCT01521975 Phase 4
32 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4
33 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4
34 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4
35 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4
36 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4
37 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4
38 Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B Unknown status NCT01913431 Phase 4
39 Prednisolone Priming Study in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4
40 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4
41 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4
42 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4
43 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B Unknown status NCT00917761 Phase 4
44 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
45 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4
46 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4
47 PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) Unknown status NCT01056172 Phase 4
48 Nutritional Support During Antiviral Therapy for Hepatitis C Unknown status NCT00841243 Phase 4
49 Twinrix Alternative Schedule Study Unknown status NCT00216229 Phase 4
50 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4

Search NIH Clinical Center for Hepatitis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis:
Promethera
Embryonic/Adult Cultured Cells Related to Hepatitis:
Adult liver progenitor cells PMIDs: 22525602 23211283 19091822 24142276 22900053

Cochrane evidence based reviews: hepatitis, chronic

Genetic Tests for Hepatitis

Genetic tests related to Hepatitis:

id Genetic test Affiliating Genes
1 Acute Hepatitis 29
2 Hepatitis 29

Anatomical Context for Hepatitis

MalaCards organs/tissues related to Hepatitis:

39
Liver, T Cells, Kidney, Testes, Brain, Thyroid, B Cells

Publications for Hepatitis

Articles related to Hepatitis:

(show top 50) (show all 26006)
id Title Authors Year
1
Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis. ( 27666584 )
2017
2
Chlorogenic acid ameliorated concanavalin A-induced hepatitis by suppression of Toll-like receptor 4 signaling in mice. ( 28088700 )
2017
3
Changes in the Prevalence of Hepatitis C Virus Infection, Non-alcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients with Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. ( 28088461 )
2017
4
A preliminary investigation on single nucleotide polymorphism rs2287622 of bile salt export pump gene in patients with chronic hepatitis C virus infection in Hunan, China. ( 28292275 )
2017
5
Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area. ( 28493307 )
2017
6
Giant symptomatic aneurysm secondary to hereditary hemorrhagic telangiectasia of a main hepatic artery with aberrant origin in superior mesenteric artery. ( 28461180 )
2017
7
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. ( 28535298 )
2017
8
Dietary flavones counteract phorbol 12-myristate 13-acetate-induced SREBP-2 processing in hepatic cells. ( 27778136 )
2017
9
Promoting effect of hepatitis B virus on the expressoin of phospholipase A2 group IIA. ( 28077172 )
2017
10
Investigation of underlying comorbidities as risk factors for symptomatic human hepatitis E virus infection. ( 28078736 )
2017
11
Tubulin alpha 8 is expressed in hepatic stellate cells and is induced in transformed hepatocytes. ( 28063004 )
2017
12
Direct-acting antivirals for hepatitis C virus induce a rapid clinical and biochemical remission of porphyria cutanea tarda. ( 28369802 )
2017
13
Viral hepatitis status does not affect survival in patients with hepatocellular carcinoma. ( 28042245 )
2017
14
A Randomized Controlled Trial to Evaluate a Potential Hepatitis B Booster Vaccination Strategy Using Combined Hepatitis A and B Vaccine. ( 28060048 )
2017
15
Covert Hepatic Encephalopathy: Can My Patient Drive? ( 28027071 )
2017
16
A collaborative study to establish the 3rd WHO International Standard for hepatitis B virus for nucleic acid amplification techniques. ( 28082100 )
2017
17
Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations. ( 28512229 )
2017
18
Genome-wide study links PNPLA3 variant with elevated hepatic transaminase after acute lymphoblastic leukemia therapy. ( 28090653 )
2017
19
Severe Aplastic Anemia following Parvovirus B19-Associated Acute Hepatitis. ( 28512588 )
2017
20
Treatment of Delta Hepatitis: Today and in the Future - A review. ( 28092214 )
2017
21
Propranolol as First Line Treatment for Life-threatening Diffuse Infantile Hepatic Hemangioma: A Case Report. ( 28056491 )
2017
22
The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-Specific T Cells. ( 27803174 )
2017
23
Hepatic Encephalopathy. ( 28079343 )
2017
24
A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naA^ve chronic hepatitis C patients in Taiwan. ( 28088273 )
2017
25
Hepatitis C virus lipoviroparticles (HCV-LVP) assemble in the endoplasmic reticulum (ER) and bud off from the ER to Golgi in COPII vesicles. ( 28515296 )
2017
26
Interleukin 10 gene single nucleotide polymorphisms in Polish patients with chronic hepatitis C: Analysis of association with severity of disease and treatment outcome. ( 27793650 )
2017
27
Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. ( 28529116 )
2017
28
An adult case of lymphangioma of the hepatoduodenal ligament mimicking a hepatic cyst. ( 28050777 )
2017
29
Single nucleotide polymorphisms of interleukins associated with hepatitis C virus infection in Egypt. ( 28368861 )
2017
30
High frequency of hepatitis E virus infection in swine from South Brazil and close similarity to human HEV isolates. ( 28089613 )
2017
31
Effect of Age (over 75A Years) on Postoperative Complications and Survival in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma. ( 28083840 )
2017
32
Hepatitis E virus seroprevalence among the general population in a livestock-dense area in the Netherlands: a cross-sectional population-based serological survey. ( 28056844 )
2017
33
Clinical development of hepatitis C virus host-targeting agents. ( 28087068 )
2017
34
Hepatitis E virus infection in anti-HEV IgG-carryinfing patients after successful HCV treatment: reactivation or reinfection? ( 28077520 )
2017
35
Prevalence and risk factors for hepatitis B and C viruses in patients with leprosy. ( 28457830 )
2017
36
Hepatic Lipodystrophy in Galloway Calves. ( 28055330 )
2017
37
Genome-wide Association Study Identifies Risk Variants for Lichen Planus in Patients With Hepatitis C Virus Infection. ( 28065765 )
2017
38
Phylogenetic analysis of Hepatitis E virus strains isolated from slaughter-age pigs in Colombia. ( 28063923 )
2017
39
HMGB1-induced autophagy: a new pathway to maintain Treg cell function during chronic hepatitis B virus infection. ( 28082516 )
2017
40
Overall Structural Model of NS5A Protein from Hepatitis C Virus and Modulation by Mutations Confering Resistance of Virus Replication to Cyclosporin A. ( 28535337 )
2017
41
Hepatic vagus nerve regulates Kupffer cell activation via I+7 nicotinic acetylcholine receptor in nonalcoholic steatohepatitis. ( 28044208 )
2017
42
Autoimmune Hepatitis Associated with Immune Thrombocytopenic Purpura. ( 28090042 )
2017
43
JHEPAT-D-17-00297 R1: Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection. ( 28527663 )
2017
44
Human Neutrophil Peptide 1 Limits Hypercholesterolemia-induced Atherosclerosis by Increasing Hepatic LDL Clearance. ( 28111237 )
2017
45
Free fatty acids or high-concentration glucose enhances hepatitis A virus replication in association with a reduction in glucose-regulated protein 78 expression. ( 27986562 )
2017
46
Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. ( 27908400 )
2017
47
The second-generation of highly potent hepatitis C virus (HCV) NS3/4A protease inhibitors: Evolutionary design based on tailor-made amino acids, synthesis and major features of bio-activity. ( 28530544 )
2017
48
Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis. ( 28533669 )
2017
49
A Acute hepatitis E mimicking a flare of disease in a patient with chronic autoimmune hepatitis. ( 28051806 )
2017
50
Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents. ( 28529212 )
2017

Variations for Hepatitis

Copy number variations for Hepatitis from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 226111 7 55054218 55242525 Amplification EGFR Hepatitis

Expression for Hepatitis

Search GEO for disease gene expression data for Hepatitis.

Pathways for Hepatitis

Pathways related to Hepatitis according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.75 HAVCR1 HAVCR2 IFNA1 TNF
2 11.22 CD81 CLDN1 IFNA1 IFNA2 SCARB1 TNF

GO Terms for Hepatitis

Cellular components related to Hepatitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 AFP F2 GPT IFNA1 IFNA2 IFNL4
2 lysosomal membrane GO:0005765 8.92 LAMTOR5 LMBRD1 SCARB1 SLC17A5

Biological processes related to Hepatitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.43 IFNA1 IFNA2
2 viral process GO:0016032 9.43 CD81 CLDN1 HAVCR1 LMBRD1 PSMA7 SCARB1
3 natural killer cell activation involved in immune response GO:0002323 9.4 IFNA1 IFNA2
4 positive regulation of chemokine production GO:0032722 9.37 HAVCR2 TNF
5 humoral immune response GO:0006959 9.33 IFNA1 IFNA2 TNF
6 negative regulation of glucose import GO:0046325 9.32 LMBRD1 TNF
7 protein localization to lysosome GO:0061462 9.26 CD81 LAMTOR5
8 viral entry into host cell GO:0046718 8.92 CD81 CLDN1 HAVCR1 SCARB1

Molecular functions related to Hepatitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IFNA1 IFNA2 IFNL4 TNF
2 type I interferon receptor binding GO:0005132 9.16 IFNA1 IFNA2
3 virus receptor activity GO:0001618 8.92 CD81 CLDN1 HAVCR1 SCARB1

Sources for Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....